Federal Circuit Affirms Pfizer Win In COVID-19 Treatment Patent Dispute
WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel affirmed a Massachusetts federal judge’s finding that a biopharmaceutical company’s patent claims were invalid as anticipated by a public disclosure...To view the full article, register now.
Already a subscriber? Click here to view full article